Technology

Rather than producing medicines through batch-wise, step-by-step processes, CONTINUUS Pharmaceuticals offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals. The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs.

Learn More »

About CONTINUUS

CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT and Novartis on Continuous Manufacturing. We specialize in end-to-end Integrated Continuous Manufacturing (ICM), with the application of novel process technologies that enable rapid production of pharmaceuticals at significantly reduced costs and better quality. With ICM, we will improve affordability and accessibility of pharmaceuticals on a global scale.

Learn More »

Newsroom

January 21, 2021
CONTINUUS Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S.

Continuous Manufacturing of Pharmaceuticals ">September 22, 2020
CONTINUUS signs Development Contract with Roche Continuous Manufacturing of Pharmaceuticals

April 16, 2020
CONTINUUS Pharmaceuticals featured in CHEManager

Newsroom »